Marché mondial du traitement de la maladie de Canavan – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché du traitement de la maladie de Canavan

La maladie de Canavan est le résultat d'une dégénérescence de la substance blanche du cerveau. Elle entraîne une augmentation de la taille de la tête. La maladie touche la population pédiatrique et les symptômes se développent généralement entre 3 et 6 mois après la naissance.

La demande du marché du traitement des maladies de Canavan a augmenté en raison de la multiplication des mutations génétiques et de l'augmentation du taux de prévalence à l'échelle mondiale, ce qui devrait stimuler la croissance du marché. De plus, la demande accrue de nouvelles options de traitement est une opportunité sur le marché qui stimulera la croissance du marché dans la période à venir.

Data Bridge Market Research analyse que le marché du traitement de la maladie de Canavan, qui était de XX millions USD en 2021, monterait en flèche pour atteindre xx millions USD d'ici 2030 et devrait connaître un TCAC de 3,9 % au cours de la période de prévision. « L'hôpital » domine le segment des utilisateurs finaux du marché du traitement de la maladie de Canavan en raison de l'augmentation du nombre de maladies et de l'augmentation des visites à l'hôpital. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement de la maladie de Canavan

Définition du marché

La maladie de Canavan est une maladie génétique rare caractérisée par une incapacité à produire une enzyme, ce qui entraîne l'accumulation d'une substance toxique dans le cerveau. Cela entraîne de graves lésions neurologiques. Le traitement thérapeutique actuel de la maladie comprend des soins de soutien et des options de traitement symptomatique.

Canavan Disease Treatment Market Dynamics

Drivers

• Increase incidence globally

The disease affects whole ethnic crowd, but arise in large occurrence in persons of Jewish descents. In this population, the carrier frequency is projected to be great as 1 out of 50 people. This increasing prevalence is driving the growth of the market

• Genetic Mutation

Canavan disease is a neurological disorder in which the brain degenerates into spongy tissue full which is small fluid-filled spaces. The disease is caused by a mutation in the ASPA gene which makes an enzyme called aspartoacylase. As per Science Direct, Mutation rates in humans have been estimated to be on the order of 10−4 to 10−6 per gene per generation. Therefore, genetic mutation is expected to drive the market growth.

Opportunities

• Research and Development Advancements

The continued research for effective treatment methods for the disease is an opportunity for the market. The Canavan Research Foundation (CRF) supports research seeking treatment or a cure for canavan disease. The current research projects include stem cell therapy, gene therapy, and metabolic approaches. Clinical trials have been ongoing in gene therapy at Robert Wood Johnson Hospital in New Jersey which is acting as opportunity for the growth of the market.

Restraints/Challenges

• Lack of awareness

. People are not much aware of the early signs and symptoms of disease to get better cure. Hence, the lack of awareness towards the disease is acting as challenge for the market

This canavan disease treatment  market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Canavan Disease Treatment  market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In April 2023, Myrtelle has secured innovative licensing and access pathway (ILAP) designation from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for its gene therapy candidate, rAAV-Olig001-ASPA, to treat Canavan disease

Global Canavan Disease Treatment Market Scope

The canavan disease treatment market is segmented on the basis of treatment, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Gene Therapy
• Drug Therapy
• Others

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Canavan Disease Treatment Market Regional Analysis/Insights

The canavan disease treatment market is analysed and market size insights and trends are provided by country, product type, application, and distribution channel as referenced above.

The countries covered in the canavan disease treatment  market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America is expected to dominate the market due to presence of major market players in the region and availability of advanced medical facilities.

Asia-Pacific is expected to account for the largest market share over coming years for the canavan disease treatment market due to high prevalence of the disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The canavan disease treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Canavan Disease Treatment  market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Canavan Disease Treatment  market. The data is available for historic period 2010-2020.

Competitive Landscape and Canavan Disease Treatment  Market Share Analysis

The canavan disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to canavan disease treatment market.

Some of the major players operating in the canavan disease treatment market are:

• Johnson & Johnson Services, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Pfizer, Inc.
• Sanofi
• F. Hoffmann-La Roche Ltée.
• Amgen, Inc.

SKU-60503